Article

Electrocautery device helps improve OAG management

Author(s):

Fort Lauderdale, FL-The Trabectome procedure (NeoMedix Corp.) with its low complication rate and high success rate suggests that it might be a promising primary surgical intervention for improved surgical management of patients with open-angle glaucoma (OAG), according to Sameh Mosaed, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology here.

"The Trabectome is a novel surgical device created to treat adult and juvenile glaucoma," said Dr. Mosaed, assistant professor of ophthalmology, department of ophthalmology, University of California, Irvine, CA. "This device allows for ablation of a segment of the trabecular meshwork and inner wall of Schlemm's canal with electrocautery. The ablation is performed under gonioscopic visualization with a modified direct goniolens designed for the procedure."

How it works

The Trabectome procedure starts with the creation of a 1.6-mm incision through the temporal clear cornea, followed by instillation of a small amount of viscoelastic. The Trabectome handpiece then is inserted into the anterior chamber and the goniolens is used to visualize the nasal angle. The handpiece has an irrigation port that maintains the anterior chamber during the procedure.

The handpiece is advanced to the nasal angle, the trabecular meshwork is identified, and the tip of the handpiece is inserted into the trabecular meshwork. The foot pedal is depressed to activate the aspiration and electrocautery.

The handpiece is advanced during electrocautery to create the arc of ablation, approximately 60° to 90° or more in some cases, until visualization becomes limited. The handpiece is removed from the eye, and a single 10-0 suture is placed through the incision. The total average operative time is approximately 20 to 30 minutes, which includes the preparation time.

IOP reduction

The investigators published the results from the initial 49 patients who underwent this procedure in June 2005.2 The procedure resulted in an approximate 40% reduction in IOP from the baseline in patients who were receiving the maximal tolerated medical therapy before the procedure.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.